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Statement of translational relevance 
The early clinical testing of novel target specific agents is an important part of improving 
anti-cancer treatment. Preclinical animal data guide initial clinical safety assumptions, 
and dogs, mice and rats are the most frequently used species. This first-in-human study 
with JNJ-38877605 revealed renal toxicity, even at sub-therapeutic doses, that was not 
predicted by the aforementioned animal models. Subsequently performed rabbit studies 
showed that species specific metabolism of quinoline ring structures of JNJ-38877605 
through aldehyde oxidase resulted in the formation of insoluble metabolites that form 
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crystal structures in the kidney leading to renal toxicity. Our findings suggest that in 
case of involvement of aldehyde oxidase, rabbit models should be used as alternative 
toxicology species.  
 
Summary 
Purpose: The receptor tyrosine kinase c-Met plays an important role in tumorigenesis 
and is a novel target for anti-cancer treatment. This phase I, first-in-human trial, 
explored safety, pharmacokinetics, pharmacodynamics and initial antitumor activity of 
JNJ-38877605, a potent and selective c-Met inhibitor.  
Experimental design: We performed a phase I dose escalation study according to the 
standard 3+3 design.  
Results: Even at sub-therapeutic doses, mild though recurrent renal toxicity was 
observed in virtually all patients. Renal toxicity had not been observed in preclinical 
studies in rats and dogs. Additional preclinical studies pointed towards the rabbit as a 
suitable toxicology model, as the formation of the M10 metabolite of JNJ-38877605 
specifically occurred in rabbits and humans. Additional toxicology studies in rabbits 
clearly demonstrated that JNJ-38877605 induced species specific renal toxicity. 
Histopathological evaluation in rabbits revealed renal crystal formation with 
degenerative and inflammatory changes. Identification of the components of these renal 
crystals revealed M1/3 and M5/6 metabolites. Accordingly, it was found that humans 
and rabbits showed significantly increased systemic exposure to these metabolites 
relative to other species. These main culprit insoluble metabolites were generated by 
aldehyde oxidase activity. Alternative dosing schedules of JNJ-3877605 and 
concomitant probenecid administration in rabbits failed to prevent renal toxicity at dose 
levels that could be pharmacologically active.  
Conclusion: Combined clinical and correlative preclinical studies suggest that renal 
toxicity of JNJ-38877605 is caused by the formation of species specific insoluble 
metabolites. These observations preclude further clinical development of JNJ-
38877605.   
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Introduction 
Tumor cell migration, invasiveness and metastasis formation are important therapeutic 
targets in oncology drug development. The hepatocyte growth factor (HGF), also known 
as scatter factor, and its receptor c-Met, play an important role in physiological 
processes such as embryological development, wound healing, tissue regeneration, 
angiogenesis, cell growth, local invasion and morphogenetic differentiation (1). In 
physiological and pathophysiological situations HGF is primarily produced by fibroblast 
like cells, whereas c-Met is expressed by epithelial cells. Aberrant expression of c-Met 
is involved in tumor progression (2, 3). Activating c-Met mutations have been identified 
in hereditary and sporadic papillary kidney cancer and gastric carcinomas, suggesting a 
potential causal role for c-Met activation in tumorigenesis (4, 5). Moreover c-Met 
amplification is a well-known event in non-small cell lung cancer especially important in 
resistance to EGFR inhibition (6). In a small subset of glioblastoma multiforme patients 
activating c-Met mutations have been reported and activation of the HGF-c-Met axis 
seems to play a role in resistance to therapy (7). Therefore, inhibiting the activity of c-
Met is a relevant objective in anti-cancer drug development.  
 
JNJ-38877605 is an orally available, nanomolar active (IC50 4.7 nM for c-Met Kinase in 
vitro) and highly selective c-Met ATP competitive kinase inhibitor (8). JNJ-38877605 
inhibits c-Met kinase with >833 fold selectivity relative to the next most potently inhibited 
kinase (Fms) of 246 kinases tested. JNJ-38877605 binds to the ATP binding site of c-
Met kinase with a high affinity that leads to a slow reversibility of binding. JNJ-38877605 
has shown a favorable safety profile in  rat and dog studies and demonstrated anti-
tumor activity in xenograft models of prostate, non-small cell lung and gastric cancer as 
well as in glioblastoma models.  
This phase I, open-label, dose-escalation study explored safety, tolerability and 
pharmacokinetics of orally administered JNJ-38877605.  
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Methods 
Patients and eligibility criteria 
This was a non-randomized, open-label, phase 1, dose-escalation study conducted at 
two participating institutions. The study was conducted in accordance with the 
International Conference on Harmonization Good Clinical Practice, in accordance with 
the ethical principles of the current Declaration of Helsinki and was approved by both 
institutional Ethics committees. All patients provided written informed consent before 
any study-related procedures were performed. All patients fulfilled the eligibility criteria 
(Supplemental methods). The population was a standard first-in-human oncology phase 
I study population (Supplemental table 1). 
 
Treatment Administration: 
Screening was performed according to protocol (Supplemental methods). The study 
was designed to determine the Maximum Tolerated Dose (MTD) for orally administered 
JNJ38877605. The compound was manufactured according to GMP standards and 
supplied by Janssen Research and Development. 
 
Selection of the Safe Starting Dose for the Clinical Study: 
The starting dose of 60 mg once daily (OD) for continuous daily administration was 
calculated based upon current recommendations for first-in-human Oncology studies in 
accordance with the recent EMEA (European Medicines Evaluation Agency) guideline 
on strategies to identify and mitigate risks for first-in-human clinical trials with 
investigational medicinal products (details: Supplemental methods).  
 
Toxicity Assessments: 
Toxicities were graded according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version 3.0 and safety assessments were performed according to 
protocol (Supplementary methods). Dose Limiting Toxicity (DLT) was defined using 
standard criteria (Supplemental methods) 
 
Determination of Maximal Tolerated Dose (MTD): 
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If 0 out of 3 patients experienced DLT during the first 21 day treatment cycle, dose 
escalation could be pursued according to protocol. If 1 out of 3 patients experienced 
DLT during the first treatment cycle, up to 3 additional patients were to be treated at that 
dose level. The MTD was defined as the highest dose level at which fewer than 2 out of 
6 patients experienced DLT. 
 
Pharmacokinetics (PK):  
Blood samples were taken at pre-specified times (see Supplemental methods) and 
analyzed quantitatively for JNJ-38877605 and the N-desmethyl metabolite, M2. For both 
compounds, Cmax, time to Cmax (tmax), elimination half life time (t1/2), area under the 
plasma concentration curve (AUC) and terminal elimination rate were calculated.  
 
Toxicology studies in the model organisms: 
Toxicology studies were performed according to ICH Topic S9. Nonclinical Evaluation 
for Anticancer Pharmaceuticals, EMEA/CHMP/ICH/646107/2008, and ICH guideline 
M3(R2) on non-clinical safety studies for the conduct of human clinical trials and 
marketing authorization for pharmaceuticals. Initially male and female rats and dogs 
were chosen as toxicology species. The choice of the toxicology species is based on a 
comparison of the metabolism pattern in hepatocytes of preclinical species and man. 
Human metabolites should be covered in the toxicology species in order to assess 
compound and metabolite related toxicity during the 1-month GLP toxicology study. 
Based on metabolite patterns in hepatocytes all human metabolites were present in rat 
and dog with the exception of an N-glucuronide, which is considered to be non-toxic. 
Therefore, rat and dog were identified as suitable species to test toxicity. 
Following the observation of renal toxicity in the clinical study we chose rabbits because 
of the presence of the glucuronide of the desmethylmetabolite (M10) in rabbit and man, 
only. A 1-month non-GLP toxicology study of JNJ-38877605 was performed in the male 
rabbit and histopathological evaluation of the kidney was performed as well as all other 
standard tissue testing and sampling. In order to find possibilities to circumvent renal 
toxicity, various intermittent dosing schedules were explored (see table 1 for the dosing 
regimen and total weekly dose). 
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Metabolite identification: 
Metabolites were determined from in vitro systems (hepatocytes and liver subcellular 
fractions), and in vivo samples (plasma, urine and kidney samples). Metabolite 
identification was performed by LC-MS, quantitative data are only available for those 
metabolites with a reference standard or metabolites with a 3H label. Solubility 
measurements were performed for some of the metabolites. 
 
Isoenzymes involved in the formation of the metabolites: 
Isoenzyme identification was performed with liver subcellular fractions. Isoenzymes 
involved in the metabolism of JNJ-38877605 were determined based on structural 
characteristics and after incubation with specific inhibitors of cytochrome P-450 and 
aldehyde oxidase (9).  
 
Histopathological evaluation: 
Rabbit kidneys were fixed by formalin immersion, then processed routinely: trimming, 
embedding, sectioning at 3-5 µm, staining with hematoxylin and eosin (HE) and 
examined under bright field. Additional frozen sections of kidney were prepared and 
counterstained with either methylene blue or Von Kossa (to detect mineralization). They 
were examined under bright field and polarization microscopy. 
 
Identification of the crystal structures in the kidneys: 
Kidney crystals detected under polarization microscopy were observed and analyzed in 
situ using Raman microscopy. Thereafter, they were harvested and analyzed with LC-
MS. 
 
Prevention of renal toxicity: 
A mechanistic study was performed to investigate the potential protective effect of 
probenecid on renal toxicity. Probenecid is known as a competitive inhibitor of organic 
acid transport in the kidney and other organs (10). After exposure to JNJ-38877605 in 
combination with probenecid, determination of pharmacokinetics (plasma, kidney, urine) 
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of JNJ-38877605, renal parameters (blood urea nitrogen and creatinine) and kidney 
histopathology were performed in male rabbits. 
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Results 
 
Toxicity in the phase I, first in human study of JNJ-38877605 
A total of 5 subjects were enrolled in the first cohort of 60 mg OD. All subjects 
experienced a rapid, though asymptomatic Grade 1 serum creatinine (SCr) increase; in 
4 patients this occurred as early as 2-3 days after the start of treatment, whereas 1 
patient completed 4 weeks of treatment prior to SCr increase. In all cases treatment 
was interrupted. In 1 patient a re-challenge with JNJ-38877605 at the same dose was 
pursued after a 3-day interruption of therapy and subsequent normalization of SCr; this 
patient again experienced a grade 1 SCr increase after which treatment was 
permanently discontinued. All subjects recovered from their SCr increase after 
permanent treatment discontinuation. Cystatin C and blood urea nitrogen showed a 
comparable pattern to SCr, whereas calculated creatinine clearance decreased 
accordingly in 4 patients (Figure 1A/B).  
To explore potential safe dose levels, an amendment was pursued allowing for dose 
levels of 10-40 mg OD to be explored. While 10 and 20 mg OD appeared to be safe 
with no indication of renal toxicity, at 40 mg OD again a rapid though asymptomatic 
grade 1 SCr increase was observed in 2/3 patients. It was then decided to discontinue 
further enrolment. During this part of the study glomerular filtration rate determination by 
Cr51 measurement was pursued in 1 patient in the 40mg cohort showing a >50% 
decrease (98 ml/min/1.73m2 pre-treatment to 45 ml/min/1.73m2 on cycle 1 day 21).  
 
Pharmacokinetic analysis of JNJ38877605 in humans  
JNJ38877605 was rapidly absorbed and showed a Cmax at 1.5-4hr after ingestion 
(Figure 1C). A short plasma half-life and virtually no accumulation after 21 days was 
found. Comparison of plasma concentrations and AUC values over the different dosing 
cohorts showed dose proportionality (Supplemental table 2). At 60 mg OD, plasma 
concentrations and AUC did not reach levels that in preclinical models resulted in 
antitumor activity.  
 
Inter-species difference in metabolism of JNJ-38877605 
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Based on a previous inter-species comparison of its metabolism, it was hypothesized 
that the renal toxicity of JNJ-38877605 that already occurred at sub-therapeutic doses, 
could possibly be explained by species specific metabolism. After incubation of JNJ-
38877605 with liver fractions and identification of the metabolites with LC/MS-MS, 
several metabolites were observed. The major metabolic pathways in humans were 
demethylation, leading to M2, that was further metabolized to M5/M6 by hydroxylation of 
the quinoline moiety and to M10 by glucuronidation. JNJ-38877605 was also 
hydroxylated at the quinoline moiety to M1/M3. (Figure 2, Supplemental table 3). A 
comparative metabolism study in hepatocytes of rat, dog, rabbit and man showed a 
species-dependent formation of M10 (major in man and rabbit) and M11 (minor) 
(Supplemental figure 1). We therefore hypothesized that M10 could play a role in the 
observed clinical renal toxicity and subsequently selected rabbit as a toxicity model.  
 
Renal effects after JNJ-38877605 administration during 1 month in rabbits  
After total weekly intake of 200, 300 and 350 mg/kg/week for 1 month, creatinine 
clearance and several other chemistry parameters started changing. At necropsy (Table 
1), rabbit kidneys showed increased weights (groups 3-6) and appeared pale (groups 4-
6). Histopathological evaluation showed an extensive and prominent degeneration with 
inflammation, congestion, fibrosis, regeneration, and granular and acicular clefts 
sometimes surrounded by giant cells (Table 1; Figure 3B-D). In frozen sections 
examined under polarization microscopy, these clefts proved to be bi-refringent 
crystalline granules and spicules (Figure 3E/F). Some of the observed changes, in 
particular the kidney weight changes and the crystal accumulation, were still present 
after a 1-month recovery period(Supplemental table 4), with a moderate increase in 
urea nitrogen and a slight increase in creatinine. 
 
As renal crystal formation was probably related to the formation of insoluble metabolites 
of JNJ-38877605 in the urine, we explored the potential protective effect of co-
administration of probenecid. As probenecid is a competitive inhibitor of organic acid 
transport in the kidney and other organs, we hypothesized that it could block the renal 
transport of JNJ-38877605 and its metabolites. In a 7-day rabbit study, probenecid co-
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administration, however, resulted in more severe clinical observations compared to 
dosing with JNJ-38877605 alone and in similar histopathological changes 
(Supplemental table 5). In addition, exposure to JNJ-38877605 decreased after 
probenecid co-administration (data not shown).  
 
Identification of the JNJ-38877605 derived metabolites in the renal crystals  
We next harvested crystals from open slides without coverslips and analyzed those with 
LC-mass spectrometry; two chemical structures were proposed based on LC-MS 
results. Additional comparison of the LC-mass UV data with TOX LC-mass UV data and 
UV reference spectra allowed for the conclusion that both proposed structures contain a 
2-hydroxyquinoline chromophore, with proposed structure 1 relating to JNJ-38877605 
metabolites M5, M6 and proposed structure 2 relating to metabolites M1, M3. Additional 
experiments showed that the M5 metabolite displayed poor solubility at with a maximum 
concentration of 2-3 µg/ml solute over a range of pH.  
We next performed mass balance studies in rats, dogs and rabbits showing that the 
excretion of JNJ-38877605 and its metabolites occurs partly through the kidney and 
rabbits and humans pre-dominantly excrete M3 and M5 in the urine. In rabbit urinary 
excretion was more important compared to rat and dog (data not shown). Plasma 
profiling showed a much lower abundance of M3 and M5 in rat and dog compared to 
rabbit and human (Table 2). These data suggested that plasma levels of M3 and M5 
and their renal excretion play a critical role in the explanation of the renal findings. 
 
Identification of the isoenzymes involved 
Identification of the isoenzymes involved in the metabolism of JNJ38877605 is based on 
studies with specific inhibitors in liver microsomes and supernatant fractions. M3 is the 
most important metabolite formed after incubation of JNJ-38877605 with human liver 
supernatant and is almost undetectable in human liver microsomes (Table 3a). This 
suggests that M3 is primarily formed by cytosolic enzymes. This is further corroborated 
by the fact that quercetin completely inhibited the formation of M3 in 12000xg fractions 
(Table 3b). Quercetin is a potent inhibitor of molybdenum hydroxylases like xanthine 
oxidase and aldehyde oxidase. Aldehyde oxidase is known to oxidize quinoline 
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moieties, therefore most probably aldehyde oxidase and not xanthine oxidase is 
involved in the metabolism of JNJ-38877605. In addition, 1-aminobenzotriazole, a 
general cytochrome P-450 inhibitor, barely inhibits the M3 formation which is in line with 
the assumptions above (Table 3b). Cytochrome P-450 3A4 is clearly involved in the 
formation of the other metabolites. M5, the equivalent of M3 but originated from the 
demethylated JNJ-38877605 (M2) was not formed in microsomes or 12000xg. Based 
on the structural similarity with M3, it is assumed that it is also formed by aldehyde 
oxidase.  
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Discussion 
In this first-in-human phase I study with the c-Met tyrosine kinase inhibitor JNJ-
38877605 renal toxicity, hampering continuation of treatment, was observed after a 
short timeframe and at virtually all, even sub-therapeutic dose levels. Based upon the at 
that time available results from preclinical studies performed in mice, rats and dogs, this 
renal toxicity had not been foreseen. Extensive additional pre-clinical research therefore 
was initiated. Based on the subsequent analysis of metabolism data, the rabbit was 
subsequently identified as a relevant toxicity model. In this model we were able to 
recognize aldehyde oxidase-dependent and  species-specific  formation of insoluble 
metabolites that induced renal toxicity through precipitation of insoluble crystals in the 
renal tubules.  
 
In the clinical study, although strongly and repeatedly considered, it was decided not to 
perform renal biopsies in any of the patients, and therefore the presence of such 
crystals in any of our patients could not be confirmed. This decision was based upon the 
clinical and ethical consideration that patients in this study had only asymptomatic 
Grade 1 serum creatinine (SCr) increases.  
 
Unfortunately, we were not able to come up with a viable strategy to circumvent renal 
toxicity in the subsequently performed rabbit studies, and therefore it was decided that 
further clinical development of JNJ-38877605 had to be stopped. 
 
With regard to the observed clinical toxicity of JNJ-38877605, it is intriguing that 
seemingly comparable observations were made In a phase I study with SGX523, 
another ATP competitive small molecule c-Met inhibitor (11). At doses exceeding 80 mg 
renal toxicity consisting of early rises in BUN and creatinine and obstructive 
nephropathy were observed. SGX523 equally showed a clean toxicity profile in rat and 
dog. SGX523 induced renal toxicity was considered probably related to the formation of 
two insoluble metabolites which were not formed in rat and dog. Subsequent studies 
performed in monkeys revealed the formation of crystals within renal tubules. The major 
urine metabolites in monkey were 2-quinolinone-SGX523 and the desmethyl metabolite 
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of 2-quinolinone-SGX523. Both metabolites were also important in plasma. Metabolites 
were formed by aldehyde oxidase. 2-quinolinone-SGX523 was formed to a much lesser 
extent in rat and was absent in dog S-9 incubations (12). 
 
The nephrotoxic metabolites could be detected in all hepatocytes cultures thus 
confounding the early signs of potential species specific generation. One hypothesis 
would be that they are formed by enzyme activity in the kidney. This hypothesis is 
corroborated by the lack of efficacy of probenecid. It is reported that the proximal, distal 
and collecting ducts of the kidney express aldehyde oxidase (13). Species specific 
aldehyde oxidase activity may contribute to the observed differences: in humans its 
activity is relatively high compared to rats and dogs (14). More conventional renal 
protective strategies such as hyper-hydration and furosemide co-administration were 
considered less suitable as we aimed for chronic administration of JNJ-38877605. In 
addition, above a certain level insoluble metabolites of JNJ-38877605 precipitate in the 
kidney and cannot be washed out. 
 
Oxidation at the quinoline moiety can be mediated by aldehyde oxidase, as suggested 
by experiments with liver subcellular fractions. M3 is the most important metabolite 
formed after incubation of JNJ-38877605 with human liver subcellular fractions but 
almost undetectable in human liver microsomes, suggesting that M3 is primarily formed 
by cytosolic enzymes such as aldehyde oxidase. An inhibition experiment with quercetin 
(9, 15) in liver subcellular fractions further supported the involvement of aldehyde 
oxidase in the formation of M3.  
 
Our observations strongly suggest that the observed renal toxicity of JNJ-38877605 is 
due to species specific metabolism and is not on target c-Met inhibitory effect. Several 
selective c-Met inhibitors have been tested in patients. Examples of well-tolerated small 
molecule c-Met inhibitors are INC280, volitinib (unpublished data) and foretinib (16). In 
addition, inhibiting HGF mediated signaling through the monoclonal antibodies 
rilotumumab and onartuzumab does not result in renal toxicity (17, 18). Thus, c-Met 
inhibition by itself is unlikely to induce on-target renal toxicity. SGX523, a structurally 
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related small molecule c-Met inhibitor did induce a comparable spectrum of renal 
toxicity, which also prompted investigators to interrupt further clinical development (11, 
12). These data underpin our observation that quinoline-containing chemical structures 
can be metabolized in a species-specific manner to form nephrotoxic poorly soluble 
metabolites explaining the observed renal toxicity of SGX523 and JNJ-38877605. 
 
Revealing rabbit as an appropriate model system allowed us to explore potential 
strategies to circumvent the renal toxicity. Unfortunately, neither alternative scheduling 
of JNJ-38877605 nor probenecid co-administration proved to be a successful strategy in 
preventing renal toxicity. A potential strategy we have not explored is inhibiting aldehyde 
oxidase itself. A list of 239 drugs inhibiting aldehyde oxidase has been reported (19). 
Raloxifene is one of these inhibitors of aldehyde oxidase (IC50 value of 0.0029 μM), and 
therefore, combining JNJ-38877605 with raloxifene could have been considered 
another preventive strategy to try to circumvent renal toxicity caused by JNJ-38877605.  
 
In conclusion, JNJ-38877605 is an orally available, nanomolar active (IC50 4.7 nM for c-
Met Kinase in vitro) and highly selective c-Met ATP competitive kinase inhibitor whose 
clinical activity was hampered by unexpected renal toxicity. Combined clinical and 
correlative preclinical studies suggest that this renal toxicity is caused by the formation 
of species specific insoluble metabolites that specifically occurs in rabbits and humans. 
These observations preclude further clinical development of JNJ-38877605. 
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Figure Legends: 
 
Figure 1: Renal toxicity in a first-in-human phase I study using JNJ-38877605. A) Serum 
creatinine levels as collected from each individual in the 60mg JNJ-38877605 over time 
were plotted. Each line represents an individual patient. B) Calculated creatinine 
clearance as determined by the Cockroft-Gould formula at each time-point is plotted. 
Each line represents an individual patient. C) Human pharmacokinetics of JNJ-
38877605 after oral administration on cycle 1 day 1 of the different patient cohorts. 
Each line represents the mean concentration over time for a dosing cohort. 
 
Figure 2: Proposed Metabolic Pathways for JNJ-38877605 Based on In Vitro Incubates 
of Liver Subcellular Fractions and Hepatocytes rat, rabbit, dog, monkey and man with 
JNJ 38877605. 
 
Figure 3: Pathologic findings of toxicity study in rabbits 
A) normal kidney. B) after 7 days, accumulation of granular material () or spicules () 
in dilated and basophilic corticotubules and collecting ducts (). Glomerules are normal 
(). C) after 1 month, there is extensive cortical damage with chronic tubulo-interstitial 
inflammation (), see prominent Bowman’s space dilation (). D) Close up of 
inflammation from figure C); regenerating tubules (basophilic) with thick basement 
membrane (), diffuse infiltrate (mainly mononuclear), congestion, interstitial fibrosis 
(), giant cells around acicular clefts (). E) Appearance of an acicular crystal under 
bright field illumination. F) same birefringent crystal than in E), under polarization. This 
foreign material deposited in tubules forms spicules as in this example or can also be 
granular.  
A-C: H&E, original magnification: 10x. D: H&E, original magnification: 20x. E, F: frozen 
section, methylene blue, original magnification: 40x. Bar: 100 µm 
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Table 1: noteworthy post-mortem changes – 1-month dosing phase 
Group  1 
(control)
2 3 4 5 6 
Dosing regimen 
in mg/kg 
 0 50 – 
3/week
100 – 
1/week 
200 – 
1/week 
100 – 
3/week 
50 – 
1/day 
Dose in 
mg/kg/week 
 0 150 100 200 300 350 
N  4a 4 4a 4 4 4 
Organ weights        
Kidney weights Fold 
change vs 
control 
17.23 g x0.93 x1.31 x1.20 x1.13 x1.16b
Microscopy        
Dilatation, 
collecting ducts 
with amorphous 
material 
Incidence 0 3 4 4 4 4 
minimal 
slight 
moderate 
 3 
0 
0 
1 
3 
0 
0 
3 
1 
1 
2 
1 
0 
2 
2 
Basophilia, 
corticotubular 
with basement 
membrane 
thickening 
Incidence 0 2 2 4 3 4 
minimal 
slight 
moderate 
 2 
0 
0 
0 
2 
0 
2 
1 
1 
0 
2 
1 
2 
0 
2 
Hypertrophy, 
corticotubular; 
with spicules and 
multinucleated 
cells 
Incidence 0 1 3 4 4 4 
minimal 
slight 
moderate 
 1 
0 
0 
1 
2 
0 
1 
2 
1 
1 
3 
0 
2 
2 
0 
Dilation, 
corticotubular, 
extending 
towards cortex 
Incidence 0 0 0 3 3 3 
minimal 
slight 
   2 
1 
2 
1 
2 
1 
Fibrosis, cortical Incidence 0 0 0 1 2 2 
minimal 
slight 
   0 
1 
2 
0 
1 
1 
a1 dead animal (mean kidney weights calculated on 3 values), bthe right kidney from 
male 13 was aplastic and the kidney weight change is underestimated in this group 
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Table 2: Metabolites of JNJ-38877605 in Plasma 
Species Metabolites UD 
 M1 M2 M3 M4 M5 M6 M7 M10  
Rat 136 64 57 15 6   1466 
Dog 31 55 40     575 
Rabbit  6388 778 603 2259 1780 395 822 22836
Man   3 387  208   2 111 
The metabolites of JNJ-38877605 were determined in urine/faeces of rat, dog and 
rabbit and in urine of man. Animals were dosed with 3H-JNJ-38877605 at 2.5 
mg/kg in rat, 2.5 mg/kg in dog and 100 mg/kg in rabbit. Humans were dosed at 60 
mg. JNJ-38877605 and its metabolites in plasma were expressed as ngeq/ml. 
Metabolites were measured at about Cmax ranging between 1 and 4h depending 
on the species. UD=unchanged drug or JNJ-38877605 
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Table 3. Identification of the enzymes causing generation of the insoluble 
metabolite M3 
3a. Formation of metabolites after incubation of JNJ-38877605 with microsomes or 
12000 xg supernatant 
Matrix  metabolites  
  M1/M2 M3 M4 UD 
Microsomes  4.46 1.21 4.07 12.8 
12000 xg  2.82 24.53 1.92 26.0 
5 μM 3H-JNJ-38877605 was incubated with human liver microsomes or 12000 xg  
during 120 min. 
 
3b. Inhibition of the metabolism of JNJ-38877605 and the formation of the major 
metabolites in human liver supernatant by an inhibitor of aldehyde oxidase and 
cytochrome P-450. 
  M1/M2 M3 M4 UD (sum of 
all metabolite 
formation) 
Inhibitor Enzyme % inhibition of metabolite formation 
Quercetin Aldehyde
oxidase 
CYP2C8 
75 94 73 112 
1-aminobenzotriazole CYP-450 58 1 70 19 
5 μM 3H-JNJ-38877605 was incubated with human 12000xg liver supernatant. 
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Figure 2 
Lolkema et al. Clinical and pre-clinical assessment of the c-Met receptor TKI JNJ-38877605 
 
N
N
N
N
N
N
N
FF
UD
M1,M3
N
N
N
N
N
N
N
FF
O
M2
N
N
N
N
N
N
HN
FF
M4
N
N
N
N
N
N
N
FF
O
M7
N
N
N
N
N
N
HN
FF
O
N
N
N
N
N
N
N
FF
GLU
O
M5,M6
N
N
N
N
N
N
HN
FF
O
N
N
N
N
N
N
HN
FF
GLU
O
N
N
N
N
N
N
HN
FF
GLU
N
N
N
N
N
N
HN
FF
glutathion
H2O
M12
M8
M9, M11
M10
hydroxylation
oxidation N-demethylation
hydroxylation
glucuronidation
glutathion conjugation
oxidation
hydroxylation
hydroxylation 
glucuronidation
Glucuronidation
hydroxylation
Research. 
on August 23, 2018. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 5, 2015; DOI: 10.1158/1078-0432.CCR-14-3258 
Figure 3 
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